Arena Pharmaceuticals Inc
Most Recent
Key Cannabis Sector Updates: Analyst Ratings and Earnings
Last week, Emerald Health Therapeutics (EMH) closed with losses of 9.4%.
Cannabis Stocks Had a Mixed Performance Last Week
Cannabis ETFs traded on a largely negative note last week.
Ups and Downs in the Cannabis Space Last Week
The cannabis space was mostly positive last week. The Horizons Marijuana Life Sciences ETF (HMMJ) and the ETFMG Alternate Harvest ETF (MJ) gained 5.2% and 4.2%, respectively.
Cannabis Updates: New Listings, Price Action, and Ratings
The cannabis sector showed some weakness last week, and the Horizons Marijuana Life Sciences ETF (HMMJ) lost 3.0% while the ETFMG Alternate Harvest ETF (MJ) lost 3.4%.
Charlotte’s Web Holdings Reports Record Harvest in 2018
Charlotte’s Web Holdings (CWBHF) posted a record harvest of 675,000 pounds last year.
How Much Upside Analysts See In Novavax Stock
Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing recombinant nanoparticle vaccines and adjuvants to market.
Semaglutide May Prove to Be an Effective Anti-Obesity Therapy
Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.
Saxenda May Continue to Lead in the Diabetes Segment in 2018
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.
XBI Remained Stable as the Markets Rallied on Higher Oil Prices
On June 8, the biotech and healthcare sectors had a mixed day and remained sluggish. The SPDR S&P Biotech ETF (XBI) gained 0.1% for the day. XBI has fallen by 16.4% on a year-to-date basis.
How Much Potential Does Saxenda Hold for Novo?
Saxenda, a glucagon-like peptide-1 (or GLP-1) analog therapy, holds 31% market share for branded anti-obesity drugs.
Arena Rose 14% in XBI’s Small-Cap Space
Arena Pharmaceuticals (ARNA) rose 14% on November 2, 2015. The stock went up on high trading volumes with ~4.7 million shares being traded.
